Aclaris Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Aclaris Therapeutics, Inc. (ACRS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -1.80% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-02-27
- Aclaris Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -1.80%.
- Aclaris Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -4.30%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | -1.80% 10-K · filed 2025-02-27 |
| 2023-12-31 | -4.30% 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |